SecBot SecBot
8-K ·Filed May 20, 2026

RIGL

RIGEL PHARMACEUTICALS INC
NEUTRAL
Impact 2/10
Horizonweeks Processed6mo ago SEC0001034842-26-000041
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Routine annual meeting filing with no material financial news. Monitor future equity grants for dilution, but no immediate trading catalyst.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$29.19
T+0 close · May 20, 2026 · via day close
Latest settled
+45.43%
T+60 · $42.45
Vs SPY
+41.13%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 21 $29.19entry
  2. T+1 · 6mo ago −0.62%α −1.06% · $29.01
  3. T+5 · 6mo ago +2.95%α +1.35% · $30.05
  4. T+20 · 5mo ago +22.58%α +22.24% · $35.78
  5. T+60 · 3mo ago +45.43%α +41.13% · $42.45
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Rigel Pharmaceuticals filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders. Shareholders approved amendments to the 2018 Equity Incentive Plan and 2000 Employee Stock Purchase Plan, adding 500,000 and 360,000 shares respectively, and ratified Ernst & Young as auditor. No director departures or officer changes occurred.

Key Facts

  • Shareholders approved amendment to 2018 Equity Incentive Plan, adding 500,000 shares
  • Shareholders approved amendment to 2000 Employee Stock Purchase Plan, adding 360,000 shares
  • All three director nominees (Hannah, Moos, Rodriguez) were elected
  • Say-on-pay and ratification of Ernst & Young as auditor passed
  • No departures, appointments, or material financial disclosures

Financial Impact

No immediate financial impact; potential future dilution from ~860,000 newly authorized shares under equity plans

dilution

Risk Factors

  • Potential future dilution from equity plan shares
  • No forward guidance or operational updates provided

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
67% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001034842-26-000041
Document: 0001034842-26-000041-index.html0001034842-26-000041
Document: 0001034842-26-000041.txt0001034842-26-000041

Track record

12 reports on RIGL

Performance horizon

1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.02% at T+60 after the May 12, 2026 report. 2 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $45.03 Now $43.73 −2.89% settles Feb 12
  2. Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $44.21 Now $43.73 −1.09% settles Feb 12
  3. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $43.91 Now $43.73 −0.41% settles Feb 8
  4. Nov 5, 202611d ago 8-K Bearish 5/10 Entry $39.65 Now $43.73 −10.29% settles Feb 4
  5. Aug 4, 202614w ago 8-K Mixed 6/10 Entry $40.48 to $50.92 Now $43.73 +8.03% ▲ +25.79% +25.60% vs SPY
  6. Jun 17, 202621w ago 8-K Neutral 4/10 Entry $32.91 to $45.35 Now $43.73 +32.88% ▲ +37.80% +35.91% vs SPY
  7. Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $32.08 to $48.67 Now $43.73 +36.32% ▲ +51.71% +47.32% vs SPY
  8. May 20, 202625w ago 8-K Neutral 2/10 Viewing Entry $29.19 to $42.45 Now $43.73 +49.81% ▲ +45.43% +41.13% vs SPY
  9. May 12, 202626w ago 8-K Bullish 7/10 Entry $32.13 to $40.17 Now $43.73 +36.10% ▲ +25.02% +20.59% vs SPY
  10. May 5, 202627w ago 8-K Bearish 7/10 Entry $26.67 to $36.81 Now $43.73 −63.97% ▼ −38.02% −35.96% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 20, 2026